MitraClip Mitral Valve Repair

What Is MitraClip Mitral Valve Repair?

MitraClip mitral valve repair is a catheter-based procedure that reduces mitral regurgitation — the backward leakage of blood through the mitral valve. A small clip is guided to the heart through a vein in the groin and fastened to the edges of the valve leaflets, drawing them together so the valve closes more effectively with each heartbeat. It is used in carefully selected patients with significant mitral regurgitation, most often when conventional open-heart surgery would carry higher risk or is not the preferred first approach.

To understand what the clip does, it helps to understand the valve. The mitral valve sits between the left atrium and the left ventricle, the two chambers on the left side of the heart. In a healthy heart it opens to let blood flow forward from the atrium into the ventricle, then closes tightly as the ventricle contracts, so that blood is pushed out to the body rather than back the way it came. In mitral regurgitation the valve fails to seal, and a portion of each heartbeat’s output leaks backwards into the left atrium. The heart compensates by working harder, and over time that extra workload strains both the heart and the lungs.

The aim of treatment is not to tidy up an abnormal image on a scan for its own sake. It is to reduce the leak enough that the heart can work more efficiently, so that breathlessness, fatigue and fluid retention may ease and the cycle of worsening heart strain can be interrupted. MitraClip does this without removing the valve and without opening the chest, which is precisely why it is considered for people in whom traditional surgery is a difficult proposition.

How does the MitraClip work?

The MitraClip works by grasping the two mitral valve leaflets at the point where the leak is greatest and clipping their edges together. This technique is known as edge-to-edge repair, and because it is delivered through a catheter rather than through surgery, it belongs to a family of treatments called transcatheter edge-to-edge repair, often abbreviated to TEER. You may also see the broader term transcatheter mitral valve repair, or TMVr, used to describe the same approach.

The idea itself is older than the device. It adapts a surgical technique known as the Alfieri stitch, in which a surgeon sutures the failing leaflet edges together to create a valve with two smaller openings instead of one large, leaking one. The clip achieves a similar “double-orifice” result, but delivers it through the blood vessels of a beating heart rather than through an open chest — which is what made the concept available to patients who could never have tolerated the original operation.

Once the clip is in place, the valve no longer opens as a single large orifice. Instead, blood flows forward through the openings on either side of the clip, while the point where the leaflets failed to meet is now held closed. The valve remains your own tissue; the clip simply changes how the leaflets come together. Before the device is permanently released, the team confirms two things on live imaging: that the leak has been meaningfully reduced, and that the valve opening remains wide enough for blood to flow forward freely. Getting both right is the essence of the procedure.

How is MitraClip different from mitral valve replacement?

MitraClip repairs your own valve rather than replacing it with a prosthetic one. That distinction matters. Replacement, whether surgical or transcatheter, removes or overrides the native valve; repair preserves it. MitraClip is also not the same as open surgical repair, in which a surgeon can reshape leaflets, implant a supporting ring and reconstruct the valve’s supporting apparatus. The clip reduces regurgitation but does not rebuild the valve’s anatomy in the way valve surgery sometimes can. For younger, fitter patients with repairable valves, surgery often remains the standard recommendation. For patients with significant symptoms and elevated surgical risk, the clip’s less invasive nature is what makes treatment possible at all — and that is a clinically meaningful difference, not a marketing one.

When mitral valve leakage starts to limit daily life

Learning that you have a leaking heart valve can be unsettling, especially once shortness of breath, fatigue or swelling begins to intrude on ordinary routines. Many people with mitral regurgitation have been told they need treatment but worry about open-heart surgery, their age, other medical conditions, or whether their heart is quietly weakening. For some, the uncertainty is as hard to live with as the symptoms themselves.

Mitral regurgitation is one of the most common heart valve diseases, and it rarely announces itself suddenly. Some people adjust to their symptoms so gradually that they do not notice how much their stamina has changed until they compare themselves with a year or two earlier. Others decline more quickly, with increasing breathlessness, repeated hospital admissions for heart failure, or difficulty lying flat at night. In the right patient, a catheter-based repair can relieve this burden without the recovery associated with open surgery — but the operative word is right. Careful selection is what separates a good result from a disappointing one, and it is the thread that runs through everything on this page.

Who May Need MitraClip Mitral Valve Repair?

Candidates for MitraClip mitral valve repair usually have moderate-to-severe or severe mitral regurgitation that is causing symptoms, affecting heart function, or contributing to recurrent heart failure. The most common symptoms are shortness of breath on exertion or at rest, reduced exercise tolerance, unusual fatigue, palpitations, swelling in the legs or ankles, and episodes of fluid build-up that need hospital treatment. Some patients also describe a persistent cough, trouble sleeping flat, or a sense that ordinary activities now demand far more effort than they used to.

Not everyone with mitral regurgitation has symptoms straight away. Some people are diagnosed after a heart murmur is heard during a routine examination, or after an echocardiogram performed for another reason. Even without obvious symptoms, a significant leak can still damage the heart over time, which is why detailed assessment matters — particularly when imaging suggests the leak is severe, or when the left ventricle begins to enlarge or weaken.

How is candidacy for MitraClip assessed?

Candidacy is assessed through a structured evaluation, not a single test. It generally begins with a clinical review and echocardiography. Transthoracic echocardiography — the standard scan through the chest wall — is usually the first imaging step. Transoesophageal echocardiography, performed via a probe passed into the food pipe, gives a far more detailed view of the valve: the direction and severity of the leak, the condition of the leaflets, and whether the anatomy is suitable for clipping. Additional testing may include electrocardiography, blood tests, chest imaging, cardiac CT in selected cases, and coronary angiography or other assessment of the heart’s blood supply when indicated.

Doctors also look beyond the valve itself. They assess left ventricular size and pumping ability, pressure in the lung circulation, the presence of atrial fibrillation, kidney function, frailty, lung disease, and any other conditions that affect both the safety of a procedure and the benefit a patient can realistically expect from it. For patients whose regurgitation is driven by heart failure, it is especially important to establish whether guideline-directed heart failure treatment has already been optimised by the treating team, since medication and device therapy remain central parts of care regardless of what happens to the valve.

Typical situations in which MitraClip is considered include:

• Significant degenerative mitral regurgitation in a patient whose risk from open-heart surgery is judged high or prohibitive
• Functional (secondary) mitral regurgitation related to heart failure that persists despite optimised medical treatment
• Persistent symptoms — breathlessness, fatigue, swelling — that limit quality of life
• Repeated hospital admissions for heart failure in the setting of mitral valve leakage
• Patients who need a less invasive approach because of age, previous cardiac surgery, lung disease, kidney disease or other serious medical conditions

Three questions sit at the heart of the decision: is the valve anatomy favourable for a clip, are the symptoms genuinely being driven by the valve leak, and is reducing the leak likely to improve how the patient feels and functions? When all three answers point the same way, MitraClip is worth serious consideration. When they do not, another path — surgery, medical optimisation, rhythm treatment or a different structural intervention — may serve the patient better. This is why specialist heart-team review is a fixed part of the pathway rather than an optional extra.

Conditions and Indications MitraClip Addresses

MitraClip is used to treat clinically significant mitral regurgitation. The condition falls into two broad categories, and the distinction is not academic — it shapes who benefits, how much, and what else needs treating alongside the valve.

Degenerative (primary) mitral regurgitation

Degenerative mitral regurgitation, also called primary mitral regurgitation, occurs when the valve itself is abnormal. The leaflets may prolapse, flail, thicken, or lose their normal supporting structures. In these patients, surgery is often the standard treatment when operative risk is acceptable, because surgical repair can provide durable correction in suitable anatomy. When surgery is judged too risky or otherwise unsuitable, MitraClip offers a less invasive alternative aimed at reducing the leak and relieving symptoms. Here the leak is the disease, so treating the leak addresses the root of the problem.

Functional (secondary) mitral regurgitation

Functional mitral regurgitation, also called secondary mitral regurgitation, occurs when the valve tissue is relatively normal but the heart muscle has enlarged or weakened, pulling the leaflets apart so they cannot close properly. This pattern is common in cardiomyopathy and chronic heart failure. In these patients, the valve leak is a consequence of the muscle disease as well as a contributor to it. MitraClip may be considered when symptoms persist despite optimised medical therapy and when the anatomical and clinical picture suggests the patient stands to gain from reducing the leak — but the clip treats the leak, not the underlying muscle disease, and expectations should be set accordingly.

What is the controversy surrounding MitraClip?

The controversy surrounding MitraClip concerns secondary mitral regurgitation: which heart-failure patients are genuinely helped by clipping the valve, and which are too far along in their muscle disease for a valve repair to change their course. Two large randomised trials in this population, published around the same time, reached different conclusions — one suggesting clear benefit in symptoms and heart failure burden, the other finding no advantage over medical therapy alone. The most widely accepted explanation is that the trials enrolled different kinds of patients. Where the regurgitation was severe relative to the size of the weakened ventricle — sometimes described as “disproportionate” — reducing the leak appeared to help. Where the ventricle was very dilated and the leak was more a bystander of advanced muscle disease, treating the valve made less difference.

The practical consequence for you is straightforward: in secondary mitral regurgitation, an honest centre will first make sure your heart failure treatment is fully optimised, then assess carefully whether your leak is a genuine driver of your symptoms before recommending a clip. A team that offers MitraClip to every heart-failure patient with a leaky valve is not reading the evidence carefully. In degenerative mitral regurgitation, this controversy does not apply in the same way — there, the main debate is simply whether surgery or a clip is the better tool for the individual patient.

MitraClip is not suitable for every patient with mitral valve disease. Some need surgery instead, particularly with complex anatomy, extensive calcification of the valve, additional valve disease requiring correction, active infection, or structural problems a clip cannot adequately treat. Others may be better served by a different transcatheter strategy or by continued medical management. A careful imaging review is what distinguishes among these possibilities.

How MitraClip Mitral Valve Repair Is Performed

The MitraClip mitral valve repair pathway begins well before the day of the procedure. Detailed echocardiographic imaging defines the valve anatomy and quantifies the leak. The care team reviews current medications, kidney function, blood counts, heart rhythm and any history of bleeding or clotting problems. In many cases, blood thinners or certain diabetes medications need temporary adjustment beforehand — a decision that belongs to the treating team, who will give specific instructions based on your individual situation. Existing records and imaging are typically reviewed in advance so the team can judge whether the anatomy looks suitable before the procedure is planned in detail.

On the day itself, the sequence generally runs as follows:

1. Preparation and anaesthesia. You are admitted and taken to a specialised cardiac catheterisation or hybrid suite. An intravenous line is placed, monitoring is connected, and the anaesthesia team reviews the plan. MitraClip is usually performed under general anaesthesia or deep sedation, partly because transoesophageal imaging is needed throughout.
2. Venous access. The team gains access through a vein in the groin. There is no chest incision and the heart is not stopped; the heart-lung machine used in open surgery is not required.
3. Reaching the left atrium. A catheter is advanced through the venous system to the right atrium. The team then performs a transseptal puncture — crossing the thin wall between the right and left atria to reach the left side of the heart. This step demands precision and is guided by live imaging.
4. Positioning the clip. The delivery catheter is steered until the clip sits above the mitral valve, aligned with the point of greatest regurgitation. Real-time transoesophageal echocardiography shows the leaflets, the jet of the leak and the device position; fluoroscopy tracks the catheters.
5. Grasping the leaflets. The clip is advanced through the valve, opened, drawn back to capture the leaflet edges, and closed. The team then studies the result on imaging.
6. Assessment before release. Nothing is made permanent until three checks are satisfied: the clip has securely grasped both leaflets, the regurgitation has been meaningfully reduced, and the valve opening remains adequate so that a new obstruction is not created. If the position is not right, the clip can be reopened and repositioned.
7. Additional clips if needed. Depending on the anatomy and the pattern of the leak, more than one clip may be placed to achieve an acceptable result.
8. Completion. Once the final clip is released, the catheters are withdrawn and the puncture site in the groin is closed. You are transferred to a monitored recovery area or a cardiac observation unit.

Procedure duration varies with valve anatomy, imaging complexity and the number of clips used. Many procedures are completed within a few hours, though the full episode of care includes preparation beforehand and monitoring afterwards.

Technology carries a great deal of the workload here, but its value lies in how it supports judgement. High-resolution echocardiography determines whether the valve is suitable in the first place and guides leaflet capture in real time. Catheter-based delivery systems reach the heart through the blood vessels rather than through an open chest. Continuous monitoring lets the team read pressure changes, heart rhythm, oxygenation and the immediate physiological effect of reducing the leak — so the decision to release the clip is made on evidence gathered in the moment, not on hope.

How serious is a mitral valve clip procedure?

A mitral valve clip procedure is a significant heart intervention, but a considerably less invasive one than open-heart surgery. There is no sternotomy, no heart-lung machine and no stopped heart, which is why it can be offered to patients for whom surgery is judged too risky. That said, it is performed inside a beating heart under general anaesthesia, and it carries real risks: bleeding or vessel injury at the groin access site, heart rhythm disturbances, injury to the leaflets, partial detachment of the clip, a residual or recurrent leak, and — uncommonly — complications serious enough to require surgery. There is also the possibility that the leak cannot be reduced as much as hoped. Your team should discuss these risks with you in the context of your own anatomy and health, because the balance of risk and benefit is different for every patient.

Is MitraClip transcatheter mitral valve repair safe?

MitraClip transcatheter mitral valve repair is an established, regulatory-approved procedure that has been performed in large numbers worldwide, and in appropriately selected patients it is generally well tolerated. No heart procedure is free of risk, and it would be dishonest to describe this one that way. What can fairly be said is that its safety profile depends heavily on three things: whether the valve anatomy genuinely suits a clip, how thoroughly the patient has been evaluated beforehand, and the experience of the team performing and imaging the procedure. Much of the safety of MitraClip is decided before anyone enters the catheterisation lab — in the quality of the imaging review and the honesty of the selection decision. A patient turned away because the anatomy is unfavourable has been served well, not poorly.

Recovery After MitraClip

Recovery after MitraClip is usually shorter and gentler than after open-heart surgery, because there is no chest wound to heal and no bypass to recover from. Most patients begin sitting up and walking once the groin access site is stable and initial monitoring is complete. Before discharge, the team typically performs follow-up echocardiography, reviews medications, and explains activity limits, wound care and follow-up appointments.

How long does it take to recover from a mitral valve clip procedure?

Recovery from a mitral valve clip procedure is measured in days to weeks rather than the months associated with open surgery. Hospital stay is often brief, though it varies with age, heart failure severity, kidney function, rhythm issues and how you feel after the procedure. The groin site needs a short period of care and restraint from heavy lifting or strenuous effort. Beyond that, the pace of recovery is set less by the procedure itself than by the condition of the heart it was performed on: a patient with well-preserved heart function tends to rebound faster than one with long-standing heart failure. Some people notice easier breathing or better stamina within days to weeks; for others the change is more gradual as the heart adapts and heart failure treatment continues. The clip is one part of a broader treatment plan, not a substitute for ongoing cardiology care.

Time Period	What Patients Can Expect
Day 1	Monitoring in hospital, assessment of the groin access site, follow-up imaging, and a gradual return to sitting up and walking.
First Week	Rest and light activity, medication review by the treating team, and attention to the access site and to symptoms such as bleeding, fever or increasing shortness of breath.
First Month	Energy levels often improve progressively. Follow-up with the cardiology team confirms valve function and fine-tunes ongoing treatment.
Longer Term	Continued heart care remains important, especially with heart failure or rhythm disorders. Periodic echocardiography is usually part of long-term follow-up.

Follow-up echocardiography after the procedure has a specific job: it confirms that the clip remains securely attached, that the reduction in the leak achieved in the catheterisation lab has held, and that forward flow through the repaired valve remains adequate. Antithrombotic medication is commonly used for a period after clip implantation while the device settles into the heart tissue; the choice of drug and its duration are individual decisions made by the treating team, particularly in patients who already take blood thinners for atrial fibrillation or other conditions.

Why Acting Early Matters

Mitral regurgitation is not always an emergency, but waiting too long can narrow your options and blunt the benefit of treatment. A leaking mitral valve places chronic volume stress on the left side of the heart. Over time the left ventricle may enlarge and weaken. Pressure can build in the lung circulation, worsening breathlessness and, in some patients, leading to pulmonary hypertension. Irregular rhythms such as atrial fibrillation may develop or become harder to control.

In heart failure, significant secondary mitral regurgitation can set up a damaging cycle: the failing ventricle worsens the leak, and the leak in turn adds to the ventricle’s workload. This can drive repeated hospital admissions, declining exercise capacity and progressive symptoms despite medication. Once heart damage becomes advanced, even a technically successful reduction of the leak may not undo the effects of years of strain — which is one reason the timing of evaluation matters as much as the choice of treatment.

Acting early does not mean rushing into a procedure. It means recognising symptoms, obtaining the right imaging, and having the case reviewed before the condition progresses further. For potential MitraClip candidates, timely assessment helps identify the window in which intervention is most likely to translate into a genuine improvement in how you feel and function.

Potential Benefits of Treatment

For appropriately selected patients, MitraClip can offer meaningful clinical advantages:

Benefit	What It Means for You
Reduced mitral regurgitation	Less backward flow through the valve may help the heart pump more efficiently and reduce strain on the lungs.
Improvement in symptoms	Many patients experience less shortness of breath, better stamina and a greater ability to manage daily activities.
Less invasive than open-heart surgery	The procedure is performed through a vein in the groin, avoiding a large chest incision and generally allowing a shorter recovery.
An option for higher-risk patients	It may make treatment possible for people who are not good candidates for conventional surgery because of age or other medical conditions.
Support for broader heart failure care	In selected patients with secondary mitral regurgitation, reducing the leak can complement medication and other heart failure therapies.

What Influences Outcomes After MitraClip?

Outcomes after MitraClip mitral valve repair depend on several interacting factors, and the most important of them is patient selection. Results are generally best when the valve anatomy suits a clip and when the symptoms or heart failure burden are truly being driven by the regurgitation. This is why careful imaging before the procedure is essential rather than optional.

The underlying cause of the leak matters just as much. Patients with degenerative regurgitation and favourable anatomy can experience substantial symptom improvement when the leak is effectively reduced, because the leak was the core problem. In secondary regurgitation, results are more closely tied to the severity of the underlying heart failure and how well medical therapy has been optimised. The clip can lift one important burden from the heart, but it does not repair a diseased heart muscle.

Other factors that shape recovery and long-term benefit include:

• How much the regurgitation is reduced during the procedure
• Baseline left ventricular function and size
• The presence of pulmonary hypertension
• Kidney function and other major medical conditions
• Frailty and general physical reserve
• Rhythm disorders such as atrial fibrillation
• Adherence to medications and follow-up care afterwards

Operator and centre experience are also relevant. MitraClip demands technical skill, but equally important is judgement: selecting patients honestly, interpreting the imaging correctly, managing anaesthesia and haemodynamics, and responding to what the pictures show during the procedure. Centres that use structured heart-team evaluation are better positioned to match the treatment to the patient rather than fitting every patient into a single strategy.

What is the average life expectancy after a mitral valve clip procedure?

There is no single figure that honestly answers this question, because life expectancy after a mitral valve clip is determined far more by the condition of the heart and the patient than by the clip itself. Someone with degenerative regurgitation, a strong ventricle and few other illnesses faces a very different outlook from someone with advanced heart failure in whom the leak is one problem among several. What can be said honestly is this: the purpose of the procedure is to reduce a leak that strains the heart and lungs, with the aim of easing symptoms and lessening the heart failure burden in patients selected because they are likely to benefit. Your own cardiologist, looking at your ventricle, your valve, your kidneys and your overall health, can give you a far more meaningful picture of your outlook than any average — and a responsible team will frame the conversation around your individual situation rather than a headline number.

How Acibadem Approaches MitraClip Evaluation

The quality of the decision-making process matters as much as the procedure itself. At Acibadem, patients considered for MitraClip are evaluated within an integrated cardiology and cardiac surgery framework that brings together interventional cardiologists, cardiac surgeons, cardiac imaging specialists, anaesthesiologists, heart failure specialists and specialised nursing teams. Complex valve cases can be reviewed by multidisciplinary boards, so recommendations reflect both the anatomical detail and the patient’s broader medical picture.

This structure exists because transcatheter mitral repair is not the right answer for everyone. Some patients benefit most from MitraClip. Others are better served by surgery, medical optimisation, rhythm treatment or a different structural heart intervention. Team-based review keeps the recommendation anchored to evidence, imaging findings, symptom burden and procedural risk rather than to a one-size-fits-all pathway.

Diagnostics follow the same logic. Echocardiography, transoesophageal imaging, cardiac CT when indicated, catheter-based assessment and pre-anaesthesia evaluation are used not as isolated tests but as parts of a structured plan to determine candidacy and procedural strategy. Reports and existing imaging are reviewed early in the pathway, which helps establish whether a full workup is a sensible next step — a practical safeguard against moving towards a procedure that detailed imaging would have ruled out.

Personalised planning is especially important in mitral valve disease. Two patients can both be told they have severe mitral regurgitation and yet need entirely different treatments, because their valve anatomy, ventricular function, age and coexisting illnesses differ substantially. The working method is built around that reality: define the mechanism of the leak precisely, assess whether a clip is feasible, optimise the patient medically, and only then recommend the path that fits the individual case.

Living With a Repaired Valve

A MitraClip does not end your relationship with cardiology; it changes what that relationship is for. After the early recovery period, care shifts to the long term: periodic echocardiography to confirm the clip is holding and the leak remains controlled, ongoing management of heart failure or rhythm disorders where they exist, and regular review of medications by the treating team. Patients with secondary regurgitation in particular remain heart failure patients whose valve has been treated — the underlying condition still needs the same attentive care it needed before.

A few practical points belong in long-term life with a clipped valve. It is sensible to tell any doctor or dentist treating you that you have an implanted valve device, since this can influence decisions about certain procedures and about protecting the heart from infection — decisions that rest with the treating clinicians rather than with a fixed rule. Good dental hygiene and prompt treatment of infections are generally encouraged in anyone with treated valve disease, because the inner lining of the heart around a repaired valve deserves protection.

Day to day, most patients gradually resume the activities their heart allows, guided by their cardiologist rather than by a fixed schedule. The honest measure of success is not the image of the valve on a scan but what the repair returns to you in practice: easier breathing, steadier energy, fewer hospital admissions, and the ability to do more of what a leaking valve had quietly taken away. For carefully selected patients, that is what MitraClip mitral valve repair is designed to deliver — a meaningful reduction of the leak, achieved without opening the chest, embedded in a long-term plan for the whole heart.